EQS-News: SHOP APOTHEKE EUROPE: STRONG ORGANIC GROWTH CONTINUES.

Full year 2022 double-digit sales growth of 14% achieved; record EUR 1.2 billion total sales.

Information
Retrieved on: 
Sunday, January 22, 2023
⚠ partially generated by AI ↴
Stock Symbol: 
Content
Key Points: 
  • Full year 2022 double-digit sales growth of 14% achieved; record EUR 1.2 billion total sales.
  • CEO Stefan Feltens comments: “SHOP APOTHEKE EUROPE’s performance remained consistent and strong in 2022.
  • Over the same period, sales of non-Rx in DACH increased by 15.1% to EUR 810 million (2021: EUR 704 million).
  • SHOP APOTHEKE EUROPE will publish the full annual report for the financial year 2022 on 7 March 2023.



EQS-News: SHOP APOTHEKE EUROPE N.V.

/ Key word(s): Preliminary Results/Development of Sales


SHOP APOTHEKE EUROPE: STRONG ORGANIC GROWTH CONTINUES.

11.01.2023 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


SHOP APOTHEKE EUROPE: STRONG ORGANIC GROWTH CONTINUES.

  • Q4 total sales up by 14% year over year to EUR 328 million.
  • Full year 2022 double-digit sales growth of 14% achieved; record EUR 1.2 billion total sales.
  • Non-Rx sales growth 17% for the full year; 2022 guidance met.
  • Active customer base up by 0.4 million in Q4 to 9.3 million (2021: 7.9 million).

Sevenum, 11 January 2023. Preliminary and unaudited numbers for SHOP APOTHEKE EUROPE N.V. indicate that the company’s full year sales grew by 13.6% year over year, to a record EUR 1.2 billion in 2022 (2021: EUR 1.06 billion). The Group consistently recorded double-digit growth from the second quarter, rounding off the year with a peak in total sales of EUR 328 million in Q4 2022, a 13.8% increase on Q4 2021. In full year 2022, non-Rx sales grew by 17.2% to EUR 1.07 billion (2021: EUR 917 million), while in Q4 sales increased by 15.2% to EUR 294 million (Q4 2021: EUR 255 million). The active customer base expanded by 0.4 million during the final quarter to reach 9.3 million at year-end, up 1.4 million customers compared to 7.9 million at the end of 2021. Customer satisfaction also remained high in Q4 – net promoter score (NPS) of 68 – and averaged 72 for the full year (2021: 68). The Group’s sales results for 2022 are fully within the guidance range that was provided in March 2022, of growing non-Rx by 15% – 25%.      

CEO Stefan Feltens comments: “SHOP APOTHEKE EUROPE’s performance remained consistent and strong in 2022. Not only did we deliver on the guidance set at the start of the year, we also continued to strengthen our position as one of the leading e-pharmacies in Europe. This is reflected by the impressive growth of our active customer base to 9.3 million – 1.4 million more active customers than in 2021– and the double-digit growth in sales to a record EUR 1.2 billion. We thank our dedicated people for this excellent performance and look forward to welcoming more customers to our pharmacy in 2023, as the shift to online continues.” 

In full year 2022, the largest segment by sales, DACH, which includes SHOP APOTHEKE EUROPE’s business activities in Germany, Austria and Switzerland, grew by 11% to EUR 940 million (2021: EUR 847 million). Over the same period, sales of non-Rx in DACH increased by 15.1% to EUR 810 million (2021: EUR 704 million). Rx sales were EUR 130 million (2021: EUR 144 million); year-over-year growths of 3.9% and 3% respectively were recorded in the past two quarters. In Q4 2022, DACH sales increased by 14.1% from EUR 229 million in Q4 2021 to EUR 261 million. In the International segment (Belgium, the Netherlands, France and Italy), sales in 2022 totaled EUR 264 million (2021: EUR 213 million), an increase of 23.9% year over year, with sales of EUR 67 million reported in Q4 2022 (Q4 2021: EUR 59 million).

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE will publish the full annual report for the financial year 2022 on 7 March 2023.


ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of Europe’s leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, over 9 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services. In preparation for the full introduction of the electronic prescriptions in Germany, the company is continuously expanding in the area of digital health services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.

 




11.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1532095



 
End of News EQS News Service

1532095  11.01.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1532095&application_name=news&site_id=jotup